London, 13 February 2015 – Unmet medical needs are leading to significant growth in the Cystic Fibrosis Market in Europe, which will post a CAGR of 35.10 percent from 2014-2019, says research firm TechNavio.
As current treatment options cannot cure the disease completely, the mortality rate of cystic fibrosis is high. The available drugs only provide symptomatic relief, such as improving lung function, removing viscous mucus or treating intestinal blockages. However, these drugs also come with a number of adverse effects.
“Drug manufacturers are capitalizing on the unmet needs in the industry, and working to develop drugs with fewer side effects that could actually leads to disease remission in patients,” says Faisal Ghaus, Vice President of TechNavio.
“Furthermore, cystic fibrosis transmembrane conductance regulator (CFTR) modulator drugs are fast becoming the preferred choice of treatment of the disease.”
The latest report from TechNavio also emphasizes growing public awareness that is directly influencing the Cystic Fibrosis Market in Europe. Various government and non-government organizations like the Cystic Fibrosis Trust in the UK, the European Cystic Fibrosis Society, Cystic Fibrosis Ireland and Child Health International organize seminars and even conduct online education sessions. These organizations also maintain blogs and collect funds for patients and their families.
TechNavio currently has more than 3000 market research reports on a huge range of topics, including:
https://www.technavio.com/%3Cp%3E%3Cstrong%3EAbout%20TechNavio%3C/strong%…
